Welcome to our dedicated page for Protagenic Therapeutics SEC filings (Ticker: PTIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protagenic Therapeutics, Inc. (PTIX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Protagenic’s biopharmaceutical business focused on neuro-active peptide and CNS therapeutics, its clinical programs, capital structure, and Nasdaq listing status.
Through this page, readers can review current reports on Form 8-K in which Protagenic describes material events such as Nasdaq notifications of non-compliance with Listing Rules 5550(b)(1) and 5250(c)(1), board changes, legal actions related to the Phytanix share exchange agreement, and other significant corporate developments. These filings explain the company’s response to a determination to delist its securities, its intention to request a hearing before a Nasdaq Hearings Panel, and the potential impact on continued trading of PTIX on the Nasdaq Capital Market.
The filings page also includes notifications of late filing on Form 12b-25 (NT 10-Q), where Protagenic outlines reasons for delays in submitting quarterly reports and indicates its expectation to file within the permitted extension period. Together with transition reports, proxy-related disclosures, and amendments to prior 8-Ks, these documents form a regulatory record of the company’s reporting practices and transactional history, including the acquisition of Phytanix Bio Inc.
Stock Titan enhances these SEC filings with AI-powered summaries that highlight key points, such as listing compliance issues, legal proceedings, and financing actions, helping readers quickly understand the significance of lengthy or technical documents. Users can also track filings related to common stock and warrants, and monitor how Protagenic’s regulatory communications reflect the status of its CNS-focused pipeline and capital markets activities over time.
Protagenic Therapeutics (PTIX) launched an at‑the‑market offering of up to $1,750,000 in common stock under its existing sales agreement with B. Riley Securities. Shares may be sold from time to time on Nasdaq as defined by Rule 415, with the Sales Agent acting as agent or principal and earning a 3.0% commission on gross proceeds. There is no escrow arrangement.
The company indicates public float of approximately $7,911,378 based on 1,927,898 non‑affiliate shares at $4.51 as of August 25, 2025, and notes it has sold $850,715 of securities in the prior 12 months under S‑3 Instruction I.B.6, which caps sales at one‑third of public float while it remains below $75 million. Net proceeds are intended primarily to acquire potential royalty and milestone revenue streams, and for working capital and general corporate purposes.
For illustration, if 585,284 shares were sold at $2.99, the company estimates immediate dilution of $3.915 per share to new investors.
Protagenic Therapeutics (PTIX): Barrett Evans filed a Form 3 initial statement of beneficial ownership effective 05/15/2025. He is identified as a Director, 10% Owner, and ex CEO.
- Common Stock: 16,233 shares, indirect via EMC2 Capital LLC.
- Preferred Series C: 787 shares, indirect via EMC2 Capital LLC.
- Preferred Series C‑1: 131,034 shares, indirect via EMC2 Capital LLC.
- Preferred Series D: 1,000 shares direct; 4,498 shares indirect via EMC2 Capital LLC; 1,000 shares indirect via Mammoth Crest Capital LLC.
The filing notes Mr. Evans was the CEO and is a Director of PTIX.
Protagenic Therapeutics, Inc. filed an amended current report to update a consent exhibit connected to its earlier acquisition of Phytanix Bio. The company previously completed a share exchange in which it acquired 100% of the common and preferred shares of Phytanix, bringing that Nevada corporation under its control.
This latest amendment revises Item 9.01 solely to update Exhibit 23.1, the consent of GreenGrowth CPAs Inc. No other parts of the prior amended report, including the historical and unaudited pro forma financial statements for the combination with Phytanix, are changed.